A pilot study to evaluate the effectiveness of intranasal Botulinum Toxin Type A Spray for adult patients with Rhinitis

Metro North Hospital and Health Service0 个研究点目标入组 15 人开始时间: 2024年6月25日最近更新: 2024年7月8日

适应症

试验速览

暂无简介。

•1. Patients greater than or equal to 18 years
•2. Clinically confirmed diagnosis of allergic or non-allergic rhinitis.
•3. Prior Radioallergosorbent test (RAST) test and immunoglobulin E ( IgE) level (as part of the patient’s standardised medical treatment).
•4. Incomplete management of symptoms despite appropriate medical treatment (intra-nasal corticosteroid and nasal douching)

•1. Patients less than 18 years
•2. Participants who are unable to provide informed consent.
•3. Participants who are pregnant, breast feeding or planning to become pregnant during study.
•4. Participants with an absolute contraindication to botulinum toxin type A specifically allergy, pregnancy, coexisting myasthenia gravis.
•5. Coexisting chronic rhinosinusitis.
•6. Subjects with known hypersensitivity or contraindications to mometasone nasal spray.
•7. Participants who have been on an active investigational therapy within 1 month prior to screening
•8. Women of childbearing potential who are not willing to use double barrier method of contraception during the study. That is:
•-Use of contraceptive pill or intrauterine device (IUD) or similar
•-and Condoms
•9. Currently on any medication that may affect the results in an unpredictable manner.
•10. The participant does not agree to comply with or is unable to meet all study requirements for the duration of the study period.
•11. Participants deemed by the investigator to be unsuitable for participation in the study.

发起方